Abattis Bioceuticals Corp. (ATTBF)

[ebota12]

I have no idea what you're trying to imply with this remark. But maybe that was your plan, to get a reply?

I'm not asking these questions to challenge HC, only to raise a point to current and potential investors about the concept "barriers to entry". The value to the CSL is there were only 18 companies approved when Abattis PR'd the license. My point was...if this so lucrative, and apparently you don't even need a scientist or functional lab to get a license, then how long can Abattis truly capitalize on this opportunity before other more respected cannabis companies jump into the testing market? And will NV even be operational in time to fully capitalize on "first mover status", to gain customers, establish trust, enjoy premiums on price, etc.

Only chance IMO is to get purchased by an LP who wants to make a long term investment in Quality Control to reduce their incremental cost per batch. I suppose if Experion executes their MMPR then Abattis can enjoy 25% of it, but that is a long ways off.